Mirus Bio Bio-Expo Live November 2025: Upstream Bioprocessing

As the gene therapy pipeline progresses from treating ultra-rare to more prevalent diseases, the demand for viral vectors, specifically AAV, is expected to increase significantly, requiring innovative solutions for large-scale production. Current AAV processes face key challenges including low productivity, high cost per dose, and non-optimal full-to-partial/empty capsid ratios.

Discover a new approach to AAV manufacturing that addresses these challenges through a unified platform solution. The platform aims to maximize upstream productivity, achieving a benchmark of greater than 1 x10^12 GC/mL with high percent full capsids. This approach, encompassing optimized components like Sovento4HEC Media and the Aviator transfection system, offers out-of-the-box performance across serotypes and production scales, simplifying process development. Learn how this new platform can deliver multi-fold titer increases, leading to significant economic savings and faster speed to clinic by reducing the variables needing optimization.